{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:52Z","timestamp":1786991212848,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaad.2019.03.017","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T13:21:02Z","timestamp":1552656062000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation"],"prefix":"10.1016","volume":"81","author":[{"given":"Emily","family":"Baumrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of herpes zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Rr-5","key":"10.1016\/j.jaad.2019.03.017_bib2","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"Morbidity Mortality Weekly Rep Recommendations Rep"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.017_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.03.017_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jaad.2019.03.017_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.jaad.2019.03.017_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib7","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","article-title":"Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study","volume":"39","author":"Hata","year":"2011","journal-title":"Infection"},{"issue":"9","key":"10.1016\/j.jaad.2019.03.017_bib9","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2019.03.017_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-015-0810-6","article-title":"The epidemiology of herpes zoster and its complications in Medicare cancer patients","volume":"15","author":"Yenikomshian","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2010.12.003","volume":"10","author":"van Assen","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bjd.14776","article-title":"Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts","volume":"176","author":"Garcia-Doval","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.017_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archdermatol.2007.28","article-title":"Systematic reviews: grading recommendations and evidence quality","volume":"144","author":"Robinson","year":"2008","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.03.017_bib16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","article-title":"Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom","volume":"138","author":"Takeshita","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.03.017_bib17","doi-asserted-by":"crossref","first-page":"e0179447","DOI":"10.1371\/journal.pone.0179447","article-title":"Increased risk of herpes zoster in patients with psoriasis: a population-based retrospective cohort study","volume":"12","author":"Tsai","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2019.03.017_bib18","first-page":"189","article-title":"Varicella-zoster virus T cell tropism and the pathogenesis of skin infection","volume":"342","author":"Arvin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2019.03.017_bib19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jaad.2019.03.017_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-\u03b1 agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jaad.2019.03.017_bib21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2019.03.017_bib23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.jaad.2019.03.017_bib24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.017_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.03.017_bib26","first-page":"1","article-title":"Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","author":"Shalom","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"10.1016\/j.jaad.2019.03.017_bib27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1468-3083.2011.04230.x","article-title":"Risk of herpes zoster in patients with psoriasis treated with biologic drugs","volume":"26","author":"Dreiher","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jamadermatol.2017.4840","article-title":"Herpes zoster rates in a large cohort of patients with systemically treated psoriasis","volume":"154","author":"Levandoski","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.017_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2013-205148","article-title":"Psoriatic arthritis treatment and the risk of herpes zoster","volume":"75","author":"Zisman","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000323736","article-title":"Ustekinumab and herpes zoster","volume":"222","author":"Failla","year":"2011","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.017_bib31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000338691","article-title":"Herpes zoster in patients treated with biologicals","volume":"224","author":"Failla","year":"2012","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.15242","article-title":"Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials","volume":"33","author":"Langley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.017_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.017_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40261-017-0500-9","article-title":"Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis","volume":"37","author":"Attia","year":"2017","journal-title":"Clin Drug Invest"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib39","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10091","key":"10.1016\/j.jaad.2019.03.017_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"10148","key":"10.1016\/j.jaad.2019.03.017_bib41","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of\u00a0risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.03.017_bib43","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.03.017_bib44","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9993","key":"10.1016\/j.jaad.2019.03.017_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jaad.2019.03.017_bib46","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jaad.2019.03.017_bib47","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.017_bib48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.03.017_bib49","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.03.017_bib51","doi-asserted-by":"crossref","first-page":"906349","DOI":"10.1155\/2015\/906349","article-title":"The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib52","first-page":"962","article-title":"Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review","volume":"30","author":"Zhang","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.03.017_bib53","doi-asserted-by":"crossref","first-page":"ofw205","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.017_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.017_bib56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2019.03.017_bib57","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","article-title":"From the medical board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis","volume":"69","author":"Wine-Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2019.03.017_bib58","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/acr.20183","article-title":"Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids","volume":"62","author":"Pileggi","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.017_bib59","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.jaad.2019.03.017_bib60","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3899\/jrheum.160685","article-title":"Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases","volume":"44","author":"Yun","year":"2017","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.03.017_bib61","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes zoster vaccination in SLE: a pilot study of immunogenicity","volume":"40","author":"Guthridge","year":"2013","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.017_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.jaad.2019.03.017_bib63","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jaad.2019.03.017_bib64","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaad.2019.03.017_bib65","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.jaad.2019.03.017_bib66","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2019.03.017_bib67","series-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in adult autologous hematopoietic stem cell transplant recipients: phase 3, randomized, placebo-controlled, ZOE-HSCT clinical trial","author":"Sullivan","year":"2018"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219304311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219304311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:49:55Z","timestamp":1759272595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219304311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0190962219304311"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.03.017","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}